NCT01736813

CCR5-blockade in Metastatic Colorectal Cancer

Treatment of Advanced Colorectal Cancer Patients With Hepatic Liver Metastases Using the CCR5-Antagonist Maraviroc (Phase I Maracon Trial)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 12 (actual)
• Sponsor: National Center for Tumor Diseases, Heidelberg · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The surface molecule CCR5 is found on tumor cells within liver metastases of colorectal cancer. Inhibition of this molecule leads to a reduction in growth signals for tumor cells and subsequent slowed or halted tumor growth. The agent for the inhibition of CCR5 has already received FDA approval for treatment of HIV and has shown little side effects and toxicities even on long term treatment. Therefore CCR5-inhibition has the potential of providing non-toxic tumor growth inhibition.

Conditions

• Colorectal Cancer
• Neoplasm Metastasis
• Liver Metastases

Interventions

Type	Name	Description
DRUG	Maraviroc	Twelve patients with 300 mg/bid

Timeline

• Start date: 2012-11-01
• Primary completion: 2013-12-01
• Completion: 2014-09-01
• First posted: 2012-11-29
• Last updated: 2017-03-22

Locations

1 site across 1 country: Germany